All eyes on gas exchange: impact of controlled arterial hypertension on cardiopulmonary function and the effects of high-intensity interval training.

J HypertensJul 16, 2026 (epub)
Clinical ResearchCardiologyPulmonology

Fabian Schwendinger, Jonathan Wagner, Christoph Hauser et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial examined the impact of controlled arterial hypertension (AH) on cardiopulmonary function in 38 adults with AH compared to 19 controls. Results indicated that adults with AH had a 6.5 ml kg-1 min-1 lower cardiorespiratory fitness (CRF). High-intensity interval training (HIIT) over 8 weeks improved CRF and certain cardio-circulatory parameters in those with AH.

Key findings

  • Adults with AH had a 6.5 ml kg-1 min-1 lower CRF compared to controls.
  • HIIT improved OUES and V̇O 2 /work rate slope in adults with AH.
  • HIIT showed inconclusive effects on pulmonary-vascular parameters like V̇E/V̇CO 2 slope.

Why it matters

Understanding the effects of arterial hypertension on cardiopulmonary function is crucial for developing effective exercise interventions. This study highlights the potential benefits of HIIT in improving fitness levels in patients with AH.

Source

PubMed · PMID 42488976

Published in J Hypertens. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.